02 January 2018

This week in PVD

A sample of the latest PH news output from around the web for your reference.




Phase 1 Trial for Camurus’ Long-acting CAM2043 Gets Underway

The first healthy participants have been injected with CAM2043 (treprostinil FluidCrystal Injection Depot) in a Phase 1 study assessing the treatment’s safety, tolerability, and pharmacokinetics in both single and repeated doses, the Swedish pharmaceutical company Camurus announced.

CAM2043 contains treprostinil, a therapy that is effective for treating pulmonary arterial hypertension (PAH).

Lung Transplantation in Pulmonary Arterial Hypertension: An Overview

With improvements in the diagnosis and treatment of pulmonary arterial hypertension (PAH) including the use of combination therapy to target multiple pathways of the disease, survival rates have increased over time.1 However, in the significant number of patients with severe PAH who do not adequately respond to medical therapy, lung transplantation is an important option that confers substantial gains in long-term survival and health-related quality of life.

PAH Long-Term Survival Predicted by Reliable Risk Calculator

The Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL) risk score (RRS) provides significant predictive value for long-term survival and changes in mortality risk in patients with pulmonary arterial hypertension (PAH) receiving riociguat, according to study findings reported in the Journal of Heart and Lung Transplantation.

Amphetamine Derivatives and the Risk of Pulmonary Arterial Hypertension: A Missing Chapter of the Story?

A paper by Irene Frachon MD, CHRU de Brest, Département de Médecine Interne et de Pneumologie, Brest, France published in the American Journal of Respiratory and Critical Care Medicine, Dec 22 2017.

Protection against monocrotaline-induced pulmonary arterial hypertension and caveolin-1 downregulation by fluvastatin in rats

Statins are Hydroxymethylglutaryl-coenzyme A reductase inhibitors, which are typically used to lower blood cholesterol. Additional beneficial effects, including improvement to pulmonary arterial hypertension (PAH), have also been confirmed. However, the mechanisms underlying this improvement have not yet been clarified. The present study was conducted to determine if fluvastatin was protective against experimental PAH development and to investigate the potential effects of fluvastatin on caveolin‑1 (cav‑1) expression. Rats were randomized to either receive a single subcutaneous injection of monocrotaline (MCT; 60 mg/kg; MCT group) or a single subcutaneous injection of MCT (60 mg/kg) followed by an oral gavage of fluvastatin (10 mg/kg) once daily until day 42 (M + F group). Rats in the MCT group received an equivalent volume of saline following the MCT injection. Six additional rats were given an equivalent volume of saline throughout as a control measure. PAH associated variables and cav‑1 protein expression were measured in each group at various times during the experimental period. Hemodynamic and morphometric analysis revealed that M + F rats developed moderate, delayed PAH. Cav‑1 western blot analysis demonstrated that cav‑1 expression was not significantly different in fluvastatin treated rats; however, MCT injured rats given saline had markedly reduced cav‑1 expression. It was concluded that fluvastatin may protect against PAH development and ameliorate MCT induced inhibition of cav‑1 expression in rats.

Is Vitamin K Deficiency the Link Between Lung and Heart Diseases?

A review investigated whether there is a potential link between vitamin K deficiency and mechanisms associated with the development of pulmonary disease.

Comments (0)

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI